Voyageur Pharmaceuticals CEO shares major progress in MRI drug innovation with Rain Cage [Video]

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) earlier this week announced significant progress in their collaboration with Rain Cage. The company disclosed that Rain Cage has successfully created vanadium metal fullerenes at scale, a world-first achievement. This breakthrough is expected to revolutionize the development of MRI and CT scan drugs by making them more effective and safer.

The company’s CEO, Brent Willis, highlighted that fullerenes can be made water and lipid-soluble, allowing for new injectable drug formulations. Studies have shown that gadolinium fullerenes can increase sensitivity by 500 times, enabling lower doses and reducing side effects. This innovation addresses current gadolinium drugs’ safety issues, which can cause brain complications.

Willis called it a “scientific breakthrough” in a recent interview with Proactive.

“It’s going to have major impact on nanoscience in many industries,” Willis said.

Voyageur Pharmaceuticals is planning to develop gadolinium, bismuth, and iodine molecules using this technology, with experimental work set to begin in 2024. The company emphasized that while the work is experimental, successful replication of …